



Sample MYZEN - CHOCO

Delta9 THC ND | THCa ND | Total THC (THCa * 0.877 + THC) ND | Delta8 THC ND

Sample ID	SD260325-011 (135833)	Matrix	Edible
Tested for	MuZen	Reported	Mar 27, 2026
Sampled	-	Received	Mar 25, 2026
Analyses executed	CAN+, 4AD, AMU, TRY, PSY, KTM, PRY	Unit Mass (g)	13.265
		Num. of Servings	6
		Serving Size (g)	2.21

CAN+ - Cannabinoids

Analyzed Mar 25, 2026 | Instrument HPLC-VWD | Method SOP-001
 The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Cannabidiol (CBD)	0.039	0.16	ND	ND	ND	ND
Cannabidiol (CBDv)	0.039	0.16	ND	ND	ND	ND
Cannabidiolbutol (CBDb)	0.011	0.03	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND	ND
Tetrahydrocannabinol (THCV)	0.049	0.16	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	ND	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	ND	ND	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	ND	ND	ND	ND
Cannabicyclol (CBL)	0.0012	0.16	ND	ND	ND	ND
Cannabichromene (CBC)	0.13	0.432	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			ND	ND	ND	ND
Total THC + Δ8THC (THCa * 0.877 + Δ9THC + Δ8THC)			ND	ND	ND	ND
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGA * 0.877 + CBG)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

KTM - Kratom

Analyzed Mar 26, 2026 | Instrument HPLC VWD | Method SOP-KTM
 The expanded Uncertainty of the Kratom analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
7-hydroxy Mitragynine (7HMG)	0.008	0.025	ND	ND	ND	ND
MGM-15 (MGM)	0.186	0.562	ND	ND	ND	ND
Mitragynine (MITG)	0.018	0.054	ND	ND	ND	ND
Speciogynine (SPEG)	0.007	0.02	ND	ND	ND	ND
Speciociliatine (SPCL)	0.004	0.011	ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Mar 26, 2026 | Instrument HPLC VWD | Method SOP-4AD
 The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESCL)	0.19	0.584	ND	ND	ND	ND
N-methyl Tryptamine (NMT)	0.004	0.013	ND	ND	ND	ND
4-Hydroxy-MET (4-HO-MET)	0.013	0.04	ND	ND	ND	ND
n,n Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilocin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4-HO-DET)	0.014	0.042	ND	ND	ND	ND
4-Acetoxy-MET (4-AcO-MET)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4-AcO-DET)	0.004	0.011	ND	ND	ND	ND
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND

AMU - Amanita Muscaria

Analyzed Mar 26, 2026 | Instrument HPLC VWD | Method SOP-039 AMU
 The expanded Uncertainty of the Amanita Muscaria analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Ibotenic Acid (IBOa)	1.025	3.105	ND	ND	ND	ND
Muscimol (MUOL)	0.19	0.576	ND	ND	ND	ND

UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: RP0611043
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Quality Assurance Manager
 Fri, 27 Mar 2026 14:36:40 -0700

PharmLabs San Diego | 6696 Mesa Ridge Rd #A, San Diego, CA 92121 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.



TRY - Tryptamine

Analyzed Mar 26, 2026 | Instrument HPLC VWD | Method SOP-TRY

The expanded Uncertainty of the Tryptamine analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level


Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Mar 26, 2026 | Instrument HPLC VWD | Method SOP-PSY

The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately $\pm 7.81\%$ at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND



UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



DEA license: **RP0611043**
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr, Quality Assurance Manager
 Fri, 27 Mar 2026 14:36:40 -0700

PharmLabs San Diego | 6696 Mesa Ridge Rd #A, San Diego, CA 92121 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368

PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2018 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.